来那度胺联合利妥昔单抗及地塞米松方案治疗难治复发性套细胞淋巴瘤的临床疗效观察

目的:评价来那度胺联合利妥昔单抗及地塞米松方案治疗难治复发性套细胞淋巴瘤的临床疗效及安全性.方法:回顾性分析25例难治复发性套细胞淋巴瘤患者临床资料,所有患者均采用来那度胺联合利妥昔单抗及地塞米松方案治疗.来那度胺15 mg/(m2·d),第1～21天,然后停药7天;利妥昔单抗每周375 mg/m2,持续4周;地塞米松...

Clinical effect of lenalidomide combined with rituximab and dexamethasone regimen in the treatment of refractory recurrent mantle cell lymphoma

Objective:To evaluate the clinical efficacy and safety of lenalidomide combined with rituximab and dexamethasone in the treatment of refractory recurrent mantle cell lymphoma.Methods:25 patients with refractory recurrent mantle cell lymphoma treated with lenalidomide plus rituximab and dexamethasone regimen were retrospectively analysed.Lenalidomide was 15 mg/(m²·d),days 1~21,then was stopped for 7 days.Rituximab was 375 mg/m² per week for 4 weeks,and dexamethasone 10 mg/d for 2 weeks,28 days for a course of treatment.All patients were followed up until March 2019.Results:After 3 courses of treatment,8 patients achieved complete remission(CR)(32.0%),6 patients with partial remission(PR)(24.0%),7 patients with stable disease(SD)(28.0%),and 4 patients with disease progression(PD)(16.0%).The total effective rate was 56.0%.The total effective rate was 64%after treatment.25 patients had a 1-year overall survival(OS)rate of 70%,and the 1-year disease-free survival(DFS)rate was 45%.No treatment-related deaths occurred in all patients.Adverse reactions were safe and controllable.Conclusion:Lenalidomide combined with rituximab and dexamethasone is safe and effective in the treatment of patients with refractory recurrent mantle cell lymphoma.The treatment-related side effects are well tolerated.This chemotherapy regimen can be used as a salvage treatment for refractory recurrent mantle cell lymphoma.